In its effort to rival GSK’s shingles vaccine Shingrix, Curevo Vaccine has circled up $110 million and recruited two former ...

The myelofibrosis drug landscape has become more crowded since Syntara decided to focus on the disease in 2020, but the ...

Amezosvatein has shown excellent immunogenicity and improved tolerability in Phase 2 study -- Medicxi leads round, joined by new investors ...

Life science companies developing bird flu vaccines are gaining attention as the avian influenza subtype H5N1 becomes an ...

Pandemic influenza remains a significant global health threat, as signalled by the circulation and cross-species transmission of avian influenza A(H5N1) viruses from the clade 2.3.4.4b, including ...

While the myelofibrosis drug landscape has become more crowded since Syntara (then Pharmaxis) decided to focus on that ...

GSK’s Arepanrix H5N1 A/American wigeon clade 2.3.4.4b vaccine was designed using recognized technology for seasonal and pandemic flu shots, the PHAC said in a release. Prior to the supply pact ...

Eli Lilly CEO Dave Ricks made $114 million last year, according to a new proxy statement, a rare instance of a health ...

AstraZeneca has beaten analysts’ expectations in its second quarter results, outshining its UK counterpart GlaxoSmithKline, which has been hit by disruption caused by the COVID-19 pandemic.

As part of a new series looking at how pharma has responded to the pandemic, Neale Belson, SVP UK & Ireland and general manager for the UK at GSK, tells us that it is “absolutely critical” to ...

The drugmaker has revamped how it packages, promotes and sells certain medicines in an effort to overcome a postpandemic ...

Under RFK Jr., HHS has canceled key vaccine meetings. Here's what that means for seasonal flu, bird flu, and childhood ...